bioAffinity Technologies case study shows CyPath Lung detects cancer in ground-glass nodules

bioAffinity Technologies, Inc.

Case study: 66-year-old former smoker with 13mm ground-glass nodule; CyPath Lung returned 'likely malignant' result.
Robotic bronchoscopy confirmed lung cancer after positive CyPath result; patient referred for surgical treatment.
Current guidelines recommend 2-5 years watchful waiting; CyPath may reduce diagnostic delay and uncertainty.
Company issued press release on September 9, 2025 highlighting real-world clinical utility of CyPath Lung.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.